ArticleReviews in urology2020
Non-muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies.
Article in Reviews in urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07728474 (LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder - Phase IIA Randomized Controlled Trial), which is not on this map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder - Phase IIA Randomized Controlled Trial
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Long non-coding RNAs as prognostic biomarkers in non-muscle invasive bladder cancer: A systematic review.Narra J · 2024Pooled it
- Dietary consumption of cruciferous vegetables and bladder cancer risk: A systematic review and meta-analysis.Frontiers in nutrition · 2022Pooled it
- Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population.International urology and nephrology · 2026Trial
- Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.The Journal of urology · 2026Article
- The Stalk Sign in Bladder Cancer: CEUS Versus MRI.Diagnostics (Basel, Switzerland) · 2026Article
- Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.Biosensors · 2026Article
- Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.Future oncology (London, England) · 2026Article
- Burden and Trends of Genitourinary Cancers Across the Americas: A GBD 2023 Analysis of Regional Socioeconomic Gradients.Cancers · 2026Article
- A machine-learning approach to predict additional treatment after Bacillus Calmette-Guérin induction in non-muscle-invasive bladder cancer.Scientific reports · 2026Article
- Anti-inflammatory Diet Index and Bladder Cancer Risk by Stage: A 22-Year Prospective Swedish Cohort Study (1998-2020).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- HMGB1, An Autophagy-Associated Gene, as a Novel Non-Invasive Diagnostic Biomarker: Clinicopathologic Correlation in Urinary Bladder Carcinoma Patients.Annals of surgical oncology · 2026Observational
- A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.Nanomedicine (London, England) · 2026Article
- TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.Research square · 2026Article
- CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasion.Cellular & molecular biology letters · 2026Article
- Diagnostic performance of narrow-band imaging and photodynamic diagnosis compared to white light cystoscopy for non-muscle invasive bladder cancer: A network meta-analysis of randomized trials.Investigative and clinical urology · 2026Article
- Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.Clinical and translational medicine · 2026Article
- Review
- Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.BJU international · 2026Article
- Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.Research and reports in urology · 2026Article
- AI-BLADE toolbox: AI-powered BLADdEr multiparametric MRI analysis for clinical application.BJR artificial intelligence · 2026Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous subclassification of urothelial carcinoma with significant variation in individual risk of recurrence and progression to muscle-invasive disease. Risk stratification by American Urological Association (AUA) and European Association of Urology (EAU) guidelines or by using nomograms/risk calculators developed from clinical trial data can help inform patient treatment decisions but may not accurately classify all patients. Risk-adapted adjuvant (post-transurethral resection of bladder tumor [TURBT]) treatment strategies using intravesical therapies are an important means of balancing disease control with potential adverse effects. Adjuvant intravesical instillation with various chemotherapy agents and bacillus Calmette-Guérin (BCG) is well studied and associated with excellent outcomes for most patients. However, upwards of 40% of patients recur within 2 years and roughly 10% progress to muscle-invasive bladder cancer. Novel approaches and agents that aim to reduce the treatment burden associated with NMIBC are increasingly needed. We review the current landscape of NMIBC as it pertains to the use of and rationale for emerging neoadjuvant chemoablative therapies.
Indexed as
Identifiers
32760227PMC7393683W3048540526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.